Layton, DM
26  results:
Search for persons X
?
1

LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE A..:

Kuo, KH ; Layton, DM ; Lal, A...
Hematology, Transfusion and Cell Therapy.  44 (2022)  - p. S11-S12 , 2022
 
?
2

RESULTS FROM A PHASE 2 STUDY OF MITAPIVAT IN ADULTS WITH NO..:

Kuo, KH ; Layton, DM ; Lal, A...
Hematology, Transfusion and Cell Therapy.  43 (2021)  - p. S28 , 2021
 
?
3

ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BL..:

Kuo, KH ; Layton, DM ; Al-Samkari, H...
Hematology, Transfusion and Cell Therapy.  43 (2021)  - p. S20 , 2021
 
?
4

Erythroenzyme disorders:

, In: Blood and Bone Marrow Pathology,
Layton, DM ; Roper, DR - p. 121-129 , 2011
 
?
6

Real-time national survey of COVID-19 in hemoglobinopathy a..:

Telfer, P ; De la Fuente, J ; Sohal, M...
https://discovery.ucl.ac.uk/id/eprint/10113720/1/10008-Article%20Text-73142-2-10-20201021.pdf.  , 2020
 
?
7

A phase 1/2 ascending dose study and open-label extension s..:

Howard, J ; Hemmaway, CJ ; Telfer, P...
https://discovery.ucl.ac.uk/id/eprint/10072013/1/Howard_blood-2018-08-868893.full.pdf.  , 2019
 
?
10

Mutation of von Hippel-Lindau tumour suppressor and human c..:

Smith, TG ; Brooks, JT ; Balanos, GM...
https://discovery.ucl.ac.uk/id/eprint/153435/1/153435.pdf.  , 2006
 
?
11

RESULTS FROM A PHASE 2 STUDY OF MITAPIVAT IN ADULTS WITH NO..:

KH Kuo ; DM Layton ; A Lal...
http://www.sciencedirect.com/science/article/pii/S2531137921001954.  , 2021
 
?
12

ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BL..:

KH Kuo ; DM Layton ; H Al-Samkari...
http://www.sciencedirect.com/science/article/pii/S2531137921001826.  , 2021
 
1-15